<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03118765</url>
  </required_header>
  <id_info>
    <org_study_id>GSP304-201</org_study_id>
    <nct_id>NCT03118765</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Dose Ranging, Parallel Group, Active (Spiriva® Respimat®) And Placebo Controlled Study To Assess Relative Bioavailability, Pharmacodynamics And Safety Of Three Doses Of Tiotropium Bromide Inhalation Solution In Subjects With Mild To Moderate Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glenmark Specialty S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glenmark Specialty S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via
      Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 24, 2017</start_date>
  <completion_date type="Actual">July 31, 2017</completion_date>
  <primary_completion_date type="Actual">July 31, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak concentrations during the dosing interval at steady-state (CmaxSS)</measure>
    <time_frame>Day 21</time_frame>
    <description>PK parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve over the dosing interval at steady state (AUC0-tauSS)</measure>
    <time_frame>Day 21</time_frame>
    <description>PK parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in trough FEV1 at 24 hours after the last dose of treatment in comparison to GSP304 placebo</measure>
    <time_frame>Day 21</time_frame>
    <description>PD parameter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount (Aetau) of tiotropium excreted in urine over the dosing interval</measure>
    <time_frame>Day 1 and Day 21</time_frame>
    <description>PK Parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of dose (Fe) of tiotropium excreted in urine over the dosing interval</measure>
    <time_frame>Day 1 and Day 21</time_frame>
    <description>PK Parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak concentrations during the dosing interval (Cmax)</measure>
    <time_frame>Day 1</time_frame>
    <description>PK Parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve over the dosing interval (AUC0-tau)</measure>
    <time_frame>Day 1</time_frame>
    <description>PK Parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of peak drug concentration over the dosing interval (tmax)</measure>
    <time_frame>Day 1 and Day 21</time_frame>
    <description>PK Parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average concentration during a dosing interval at steady state (CavSS)</measure>
    <time_frame>Day 21</time_frame>
    <description>PK Parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (Rac)</measure>
    <time_frame>Day 21</time_frame>
    <description>PK Parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in peak FEV1 within 12 hours post-dose</measure>
    <time_frame>Day 1 and Day 21</time_frame>
    <description>PD Parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in forced vital capacity (FVC)</measure>
    <time_frame>Day 1 and Day 21</time_frame>
    <description>PD Parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in time-normalized area under the curve for FEV1 measured over 12 hours</measure>
    <time_frame>Day 1 and Day 21</time_frame>
    <description>PD Parameter</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Test Treatment T1: GSP304 Inhalation Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Test Treatment T2: GSP304 Inhalation Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Test Treatment T3: GSP304 Inhalation Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Test Treatment T4: GSP304 Placebo Inhalation Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Test Treatment T5: Spiriva® Respimat® inhalation spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSP304 (tiotropium bromide) Inhalation Solution</intervention_name>
    <description>Once daily (QD) oral inhalation using a nebulizer</description>
    <arm_group_label>Test Treatment T1: GSP304 Inhalation Solution</arm_group_label>
    <arm_group_label>Test Treatment T2: GSP304 Inhalation Solution</arm_group_label>
    <arm_group_label>Test Treatment T3: GSP304 Inhalation Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSP304 Placebo Inhalation Solution</intervention_name>
    <description>Once daily (QD) oral inhalation using a nebulizer</description>
    <arm_group_label>Test Treatment T4: GSP304 Placebo Inhalation Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spiriva® Respimat® inhalation spray</intervention_name>
    <description>Once daily (QD) oral inhalation</description>
    <arm_group_label>Test Treatment T5: Spiriva® Respimat® inhalation spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects ≥40 years and ≤85 years of age at the time of consent.

          -  Subject must have a primary diagnosis of mild or moderate COPD defined as
             post-bronchodilator FEV1/FVC ratio of &lt;70% and FEV1 of ≥50% of predicted normal value
             as per the NHANES III predicted normal values at screening.

          -  Willing to stop all other COPD medications or other medications which will interfere
             with the study results for the entire duration of the study, except
             albuterol/salbutamol as needed.

          -  Current or ex-smoker with ≥10 pack-year smoking history.

        Exclusion Criteria:

          -  Subjects with a chest x-ray/CT scan that suggests a diagnosis other than COPD (eg,
             pneumonia, other infection, atelectasis, or pneumothorax or other active/ongoing
             pulmonary conditions) and taken within 6 months prior to study start. If there is no
             chest x-ray or CT scan taken within 6 months prior to study start, or if recent
             results are unavailable for review, a chest x-ray must be performed.

          -  Use of oral/parenteral corticosteroids or antibiotics for COPD within 6 weeks or depot
             corticosteroids within 3 months prior to screening or subject has had a change in dose
             or type of any medications for COPD within 14 days before screening.

          -  Hospitalization for COPD exacerbation or pneumonia within 3 months prior to screening.

          -  Subjects with a history of asthma, with the exception of outgrown childhood asthma,
             defined as transient wheezers outgrown by 5 years of age.

          -  Subject has a known history of alpha 1 antitrypsin deficiency-related emphysema.

          -  Subject requires nocturnal oxygen or continuous supplemental oxygen therapy.

          -  Subject with history of a positive result for HBsAg or HCV antibody.

          -  Subject is known to be seropositive for human immunodeficiency virus.

          -  Female subject is pregnant or lactating.

          -  Subject has a history of allergic reaction to the anti-cholinergic or any components
             of the study medications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia Caracta, MD FCCP</last_name>
    <role>Study Director</role>
    <affiliation>Glenmark Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glenmark Investigational Site 23</name>
      <address>
        <city>Andalusia</city>
        <state>Alabama</state>
        <zip>36420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 12</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 14</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 17</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 19</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 10</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 24</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 16</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 6</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 20</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 21</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 13</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 18</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 9</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 5</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 22</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 8</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 11</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504-9741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 3</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <zip>29640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 2</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 4</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 1</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 15</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 7</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 25</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>September 18, 2017</last_update_submitted>
  <last_update_submitted_qc>September 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

